Peerbridge Health has announced the launch of its COR-INSIGHT trial, which will validate the screening and diagnostic capabilities of its Peerbridge Cor ambulatory electrocardiography (ECG) wearables. The trial seeks to “revolutionise” cardiovascular and cardiopulmonary monitoring and screening by providing a seamless, non-invasive alternative to traditional diagnostic modalities, a company press release notes.
COR-INSIGHT will leverage two new, proprietary artificial intelligence (AI) SaMD platforms: CardioMIND, an ECG+ analytical pipeline for cardiovascular indications and sleep disorder; and CardioQSync, a quantum resonance-based approach for extraction of cardiopulmonary and haemodynamic indications from respiratory ECGs.
According to Peerbridge Health, the trial is the first to prospectively evaluate multiplexed, on-demand diagnostics directly from continuous ECGs in hospital and home settings, integrating data-rich metrics for more than 30 different indications. The trial will enrol up to 15,000 participants from diverse demographics, ensuring robust data that reflect real-world clinical challenges, the company states. Peerbridge Health says that, in addition to its own sites, it will also be partnering with the HeartX programme to expand participation with leading cardiologists at HCA, Mercy Health and Louisiana Cardiology Associates in the USA in the first quarter of 2025.
By eliminating the present reliance on imaging, catheter-based techniques, and biochemical assays, COR-INSIGHT promises a “paradigm shift” in diagnostic precision and accessibility via a single, low-burden Cor ECG wearable, the company also claims.
“This trial represents an exciting leap forward in inexpensive, remote patient care,” said Chris Darland, chief executive officer (CEO) of Peerbridge Health. “The COR-INSIGHT trial allows us to provide over 30 cardiac and cardiopulmonary indications, all from one simple wearable ECG study. Just as important as the clinical innovation is our ability to deliver these insights to clinicians at ultra-low cost. Bringing inexpensive, hospital-grade diagnostics to a patient’s doorstep is a critical first step to reaching tens of millions of underserved patients and communities today.”
Peerbridge Health’s belief is that the COR-INSIGHT trial underscores the versatility of its Cor wearable, which aims to cater to patients across the clinical spectrum—from asymptomatic individuals to critically ill patients, and those awaiting procedures like transcatheter aortic valve replacement (TAVR) or implantable cardioverter defibrillator (ICD) placement. The trial is designed to provide monitoring in diverse settings, including outpatient, in-hospital and home environments, and—if successful—will have a “far-reaching impact” across the cardiology space.
